$XBI $91.85 | -3.3%
Covid Updates
$AVIR -3.7% Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications source
Pipeline Updates
$WVE -3.8% Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides. source
$IMUX -5.7% Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor. source
$SYRS -6.8% Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS. source
$GLPG -4.1% Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress. source
$EVOK +2.2% Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI. source
$PDSB -0.7% PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer. source
$CRSP -5.2% CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) source
$TCON -3.3% TRACON Pharmaceuticals Announces Initiation Of Randomized Phase 2 Trial Of TRC102 In Lung Cancer Sponsored By The National Cancer Institute source
$JAZZ 0% Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule source
$ONCY -1.0% Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial source
$LOGC -54.8% LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program source
$TARS -14.2% Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility source
Business Updates
$HTBX -7.0% Heat Biologics Announces Planned Transfer to the NYSE American. source
$XBIT -4.4% XBiotech Inks Clinical Manufacturing Deal. source
Posted by FS/JM
Comments